Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.51 is 66% above its 5-year average of -1.48, near the high end of its 5-year range (-5.52–-0.12).
32.89% above its 12-month average of -0.76.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.16.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 9 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:06:56.871Z. Historical observations retain their original dates. Historical series through 2023-03-24.
EARNINGS PER SHARE (EPS)
-0.51
EARNINGS PER SHARE (EPS) AVG TTM
-0.76
EARNINGS PER SHARE (EPS) AVG 3Y
-0.68
EARNINGS PER SHARE (EPS) AVG 5Y
-1.48
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+32.89%
CURRENT VS 3Y AVG
+24.72%
CURRENT VS 5Y AVG
+65.58%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Humacyte, Inc.
Market Cap
$84.87M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.76
3Y Avg
-0.68
5Y Avg
-1.48
Market Cap
$84.75M
Earnings Per Share (EPS)
-1.88
TTM Avg
-2.06
3Y Avg
-2.07
5Y Avg
-1.66
Market Cap
$85.24M
Earnings Per Share (EPS)
-1.18
TTM Avg
-4.40
3Y Avg
-32.48
5Y Avg
-54.06
Market Cap
$84.17M
Earnings Per Share (EPS)
-0.22
TTM Avg
-0.23
3Y Avg
-0.23
5Y Avg
-0.24
Market Cap
$85.02M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.58
3Y Avg
-0.69
5Y Avg
-0.67
Market Cap
$86.43M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.09M
Earnings Per Share (EPS)
-0.60
TTM Avg
-0.82
3Y Avg
-0.86
5Y Avg
-0.88
Market Cap
$87.75M
Earnings Per Share (EPS)
0.07
TTM Avg
-0.09
3Y Avg
-1.24
5Y Avg
-1.25
Market Cap
$81.82M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.32
3Y Avg
-0.23
5Y Avg
-0.23
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $84.87M | -0.51 | -0.76 | -0.68 | -1.48 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | -1.88 | -2.06 | -2.07 | -1.66 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.24M | -1.18 | -4.40 | -32.48 | -54.06 |
| MediciNova, Inc. (MNOV)vs › | $84.17M | -0.22 | -0.23 | -0.23 | -0.24 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.02M | -0.19 | -0.58 | -0.69 | -0.67 |
| Conexeu Sciences Inc. (CNXU)vs › | $86.43M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.09M | -0.60 | -0.82 | -0.86 | -0.88 |
| CareCloud, Inc. (CCLD)vs › | $87.75M | 0.07 | -0.09 | -1.24 | -1.25 |
| Citius Oncology, Inc. (CTOR)vs › | $81.82M | -0.48 | -0.32 | -0.23 | -0.23 |
| LENSAR Inc (LNSR)vs › | $81.67M | N/A | -2.80 | -2.22 | -2.13 |
Trailing EPS (TTM)
$-0.51
Forward EPS (Est.)
$-0.40
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.26 |
| 2024-12-31 | -1.26 |
| 2023-12-31 | -1.07 |
| 2022-12-31 | -0.12 |
| 2021-12-31 | -0.66 |
| 2020-12-31 | -5.52 |
